KPRX [NASD]
Kiora Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own0.70% Shs Outstand12.66M Perf Week13.21%
Market Cap6.00M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float12.40M Perf Month16.01%
Income-16.40M PEG- EPS next Q-0.24 Inst Own23.40% Short Float1.47% Perf Quarter-28.02%
Sales- P/S- EPS this Y-0.30% Inst Trans0.81% Short Ratio0.62 Perf Half Y-70.20%
Book/sh0.73 P/B0.62 EPS next Y1.20% ROA-79.70% Target Price7.12 Perf Year-87.60%
Cash/sh0.59 P/C0.76 EPS next 5Y- ROE-131.90% 52W Range0.35 - 6.43 Perf YTD-70.20%
Dividend- P/FCF- EPS past 5Y39.90% ROI- 52W High-93.00% Beta0.81
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low29.80% ATR0.06
Employees14 Current Ratio5.60 Sales Q/Q- Oper. Margin- RSI (14)56.74 Volatility15.27% 17.14%
OptionableNo Debt/Eq0.00 EPS Q/Q-28.70% Profit Margin- Rel Volume0.19 Prev Close0.45
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume294.23K Price0.45
Recom2.00 SMA2011.52% SMA505.09% SMA200-54.04% Volume56,416 Change0.00%
Jul-05-22 06:45AM  
Jun-27-22 06:53AM  
May-31-22 04:30PM  
Apr-25-22 06:45AM  
Apr-15-22 09:00AM  
Mar-21-22 06:45AM  
Mar-18-22 12:00PM  
06:45AM  
Feb-08-22 06:45AM  
Feb-01-22 06:45AM  
Jan-05-22 07:00AM  
Dec-15-21 07:00AM  
Dec-14-21 07:15AM  
Nov-15-21 07:30AM  
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.